FDA Keeps Controversial Diabetes Drug on the Market

The Food and Drug Administration announced Wednesday it will add its toughest type of warning to prescribing instructions for the widely sold diabetes drug Avandia instead of taking it off the market. Although a review of 42 studies of the drug earlier this year linked it to a 43 percent greater risk of heart attacks, other longer-term data did not confirm a heightened risk of heart attack, the agency said when it announced the new black box warnings.